

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – December 11, 2019 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Skrepnek

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum – See Appendix A

- A. Acknowledgment of Speakers for Public Comment
- B. Changes to Public Comment Procedure

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix B

- A. November 13, 2019 DUR Minutes – Vote
- B. November 13, 2019 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Action Item – Maintenance Drug List – See Appendix C

- A. Maintenance Drug List – Vote

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/Atopic Dermatitis Prescriber Specialty Analysis – See Appendix D

- A. Pharmacy Helpdesk Activity for November 2019
- B. Medication Coverage Activity for November 2019
- C. Atopic Dermatitis Prescriber Specialty Analysis

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Eticovo™ (Etanercept-ykro), Hadlima™ (Adalimumab-bwwd), Hyrimoz™ (Adalimumab-adaz), Rinvoq™ (Upadacitinib), and Skyrizi™ (Risankizumab-rzaa) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Elzonris® (Tagraxofusp-erzs) and Inrebic® (Fedratinib) – See Appendix F

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Aemcolo™ (Rifamycin), Motegrity™ (Prucalopride), Zelnorm™ (Tegaserod), and Ibsrela® (Tenapanor) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Drizalma Sprinkle™ [Duloxetine Delayed-Release (DR) Capsules], Spravato™ (Esketamine Nasal Spray), and Citalopram 20mg/10mL, Escitalopram 10mg/10mL, and Fluoxetine 20mg/5mL (Unit Dose Cups) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Bevyxxa® (Betrixaban) and to Update the Current Xarelto® (Rivaroxaban) Prior Authorization Criteria – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Van, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Avaclyr™ (Acyclovir 3% Ophthalmic Ointment) – See Appendix J

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

12. Action Item – Annual Review of Thrombocytopenia Medications – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Thrombocytopenia Medications
- C. Prior Authorization of Thrombocytopenia Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Thrombocytopenia Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. Annual Review of Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications and 30-Day Notice to Prior Authorize Duaklir® Pressair® (Aclidinium Bromide/Formoterol Fumarate) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. Duaklir® Pressair® (Aclidinium Bromide/Formoterol Fumarate) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Maintenance Asthma and COPD Medications
- H. Utilization Details of Inhaled Corticosteroids

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorization Scenesse® (Afamelanotide) and Givlaari™ (Givosiran) – See Appendix M

- A. Introduction
- B. Market News and Updates
- C. Scenesse® (Afamelanotide) Product Summary
- D. Givlaari™ (Givosiran) Product Summary
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

15. Annual Review of Soliris® (Eculizumab) and 30-Day Notice to Prior Authorize Ultomiris® (Ravulizumab-cwvz) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Soliris® (Eculizumab)
- C. Prior Authorization of Soliris® (Eculizumab)
- D. Market News and Updates

- E. Ultomiris® (Ravulizumab-cwvz) Product Summary
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. Action Item – Annual Review of Muscular Dystrophy Medications – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Muscular Dystrophy Medications
- C. Prior Authorization of Muscular Dystrophy Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

17. Annual Review of Carbaglu® (Carglumic Acid) – See Appendix P

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Carbaglu® (Carglumic Acid)
- D. Prior Authorization of Carbaglu® (Carglumic Acid)
- E. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

18. Industry News and Updates – See Appendix Q

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

20. Future Business* (Upcoming Product and Class Reviews)

No live meeting scheduled for January 2020. January 2020 will be a packet only meeting.

- A. Revcovi® (Elapegedemase-lvlr)
- B. Gamifant® (Emapalumab-lzsg)
- C. Glaucoma Medications
- D. Insomnia Medications
- E. Firdapse® (Amifampridine)
- F. Korlym® (Mifepristone)

**Future business subject to change.*

21. Adjournment